TNFSF11 and osteoporosis: Moreover, wild type mice treated with a specific S1PR2 antagonist (JTE013) changed monocyte migration behavior induced by RANKL by enhancing monocyte percentage in the blood and alleviated osteoporosis induced by RANKL [25].